Midgard Science

Chongqing Sintaho Pharmaceutical Co., Ltd.

Chongqing, China en.sintaho.com

From their website, Nov 2026

Work here? Claim this listing

About

Chongqing Sintaho Pharmaceutical Co., Ltd. is an API enterprise founded in 2016 in Banan District, Chongqing, China. It provides R&D, production, registration, domestic and international marketing of APIs, with business focused on high-potency/cytotoxic APIs, peptides, and XDC compounds.

Services

  • API R&D

    Develops active pharmaceutical ingredients across its business segments.

  • API production

    Manufactures APIs through its GMP supporting systems and dedicated production lines.

  • API registration support

    Supports registration activities for APIs.

  • Domestic and international API marketing

    Markets APIs in China and overseas markets.

  • CDMO services

    Provides contract development and manufacturing services for global partners.

  • CMO services

    Provides contract manufacturing services for global partners.

  • High-potency API development and manufacturing

    Works on high-potency and cytotoxic API programs using dedicated production lines.

  • Peptide development and manufacturing

    Develops and manufactures peptide products, including GLP-1 APIs.

  • XDC compound development and manufacturing

    Develops and manufactures XDC compounds and related linker-payload combinations.

  • Structural modification

    Offers structural modification as part of its C(D)MO portfolio.

  • Regulatory filing support

    Supports DMF, CEP, and ASMF filings.

  • Process scaling

    Scales processes from gram to hundred-kilogram batches.

  • Commercial supply

    Provides commercial supply for API and related projects.

  • Full-life-cycle management

    Supports post-approval change management, CPV, and responses to pharmacopoeia method revisions.

Capabilities

Assays and studies
Peptides · Small molecules · HPLC · Immunogenicity · HPLC purity · Single-impurity control · Impurity profiling · Structural characterization · Immunogenicity risk assessment · Genotoxic impurity (GTI) control
Scale and capacity
Approximately 55,000 m² of GMP-compliant manufacturing space · 1,500 kg-per-annum peptide production line for GLP-1 APIs · Commercial-scale manufacturing of high-potency compounds up to 50 kg

Instruments and platforms

  • Fully closed isolator systems

Modalities and species

Modalities
Small molecule · ADC · Peptide

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GLPSelf-reported

  • GMPSelf-reported

    Scope: long-time GMP compliance

Company

Type
CRDMO
Founded
2016

Locations

Based in
Chongqing, China
Sites
Chongqing, China
Serves
China, United States, Canada, European Union, more than 30 countries

Similar labs

Work here? Claim this listing